BACKGROUND: Debates over legalisation of physician-assisted suicide (PAS) or euthanasia often warn of a "slippery slope", predicting abuse of people in vulnerable groups. To assess this concern, the authors examined data from Oregon and the Netherlands, the two principal jurisdictions in which physician-assisted dying is legal and data have been collected over a substantial period. METHODS: The data from Oregon (where PAS, now called death under the Oregon Death with Dignity Act, is legal) comprised all annual and cumulative Department of Human Services reports 1998-2006 and three independent studies; the data from the Netherlands (where both PAS and euthanasia are now legal) comprised all four government-commissioned nationwide studies of end-of-life decision making (1990, 1995, 2001 and 2005) and specialised studies. Evidence of any disproportionate impact on 10 groups of potentially vulnerable patients was sought. RESULTS: Rates of assisted dying in Oregon and in the Netherlands showed no evidence of heightened risk for the elderly, women, the uninsured (inapplicable in the Netherlands, where all are insured), people with low educational status, the poor, the physically disabled or chronically ill, minors, people with psychiatric illnesses including depression, or racial or ethnic minorities, compared with background populations. The only group with a heightened risk was people with AIDS. While extralegal cases were not the focus of this study, none have been uncovered in Oregon; among extralegal cases in the Netherlands, there was no evidence of higher rates in vulnerable groups. CONCLUSIONS: Where assisted dying is already legal, there is no current evidence for the claim that legalised PAS or euthanasia will have disproportionate impact on patients in vulnerable groups. Those who received physician-assisted dying in the jurisdictions studied appeared to enjoy comparative social, economic, educational, professional and other privileges.
BACKGROUND: Debates over legalisation of physician-assisted suicide (PAS) or euthanasia often warn of a "slippery slope", predicting abuse of people in vulnerable groups. To assess this concern, the authors examined data from Oregon and the Netherlands, the two principal jurisdictions in which physician-assisted dying is legal and data have been collected over a substantial period. METHODS: The data from Oregon (where PAS, now called death under the Oregon Death with Dignity Act, is legal) comprised all annual and cumulative Department of Human Services reports 1998-2006 and three independent studies; the data from the Netherlands (where both PAS and euthanasia are now legal) comprised all four government-commissioned nationwide studies of end-of-life decision making (1990, 1995, 2001 and 2005) and specialised studies. Evidence of any disproportionate impact on 10 groups of potentially vulnerable patients was sought. RESULTS: Rates of assisted dying in Oregon and in the Netherlands showed no evidence of heightened risk for the elderly, women, the uninsured (inapplicable in the Netherlands, where all are insured), people with low educational status, the poor, the physically disabled or chronically ill, minors, people with psychiatric illnesses including depression, or racial or ethnic minorities, compared with background populations. The only group with a heightened risk was people with AIDS. While extralegal cases were not the focus of this study, none have been uncovered in Oregon; among extralegal cases in the Netherlands, there was no evidence of higher rates in vulnerable groups. CONCLUSIONS: Where assisted dying is already legal, there is no current evidence for the claim that legalised PAS or euthanasia will have disproportionate impact on patients in vulnerable groups. Those who received physician-assisted dying in the jurisdictions studied appeared to enjoy comparative social, economic, educational, professional and other privileges.
Authors: Marije L van der Lee; Johanna G van der Bom; Nikkie B Swarte; A Peter M Heintz; Alexander de Graeff; Jan van den Bout Journal: J Clin Oncol Date: 2005-08-22 Impact factor: 44.544
Authors: Agnes van der Heide; Bregje D Onwuteaka-Philipsen; Mette L Rurup; Hilde M Buiting; Johannes J M van Delden; Johanna E Hanssen-de Wolf; Anke G J M Janssen; H Roeline W Pasman; Judith A C Rietjens; Cornelis J M Prins; Ingeborg M Deerenberg; Joseph K M Gevers; Paul J van der Maas; Gerrit van der Wal Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: P J van der Maas; G van der Wal; I Haverkate; C L de Graaff; J G Kester; B D Onwuteaka-Philipsen; A van der Heide; J M Bosma; D L Willems Journal: N Engl J Med Date: 1996-11-28 Impact factor: 91.245
Authors: Mette L Rurup; Bregje D Onwuteaka-Philipsen; Agnes van der Heide; Gerrit van der Wal; Paul J van der Maas Journal: J Am Geriatr Soc Date: 2005-07 Impact factor: 5.562
Authors: P J Bindels; A Krol; E van Ameijden; D K Mulder-Folkerts; J A van den Hoek; G P van Griensven; R A Coutinho Journal: Lancet Date: 1996-02-24 Impact factor: 79.321
Authors: Laura A Petrillo; Elizabeth Dzeng; Krista L Harrison; Lindsay Forbes; Benjamin Scribner; Barbara A Koenig Journal: Am J Public Health Date: 2017-04-20 Impact factor: 9.308
Authors: Judith A C Rietjens; Paul J van der Maas; Bregje D Onwuteaka-Philipsen; Johannes J M van Delden; Agnes van der Heide Journal: J Bioeth Inq Date: 2009-07-28 Impact factor: 1.352
Authors: Hilde Buiting; Johannes van Delden; Bregje Onwuteaka-Philpsen; Judith Rietjens; Mette Rurup; Donald van Tol; Joseph Gevers; Paul van der Maas; Agnes van der Heide Journal: BMC Med Ethics Date: 2009-10-27 Impact factor: 2.652